Trial Profile
Maternal pertussis (Tdap) vaccination and its effects on the immune response of the new-born up to 12 months of age.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Pharmacodynamics
- Acronyms MIKI
- 22 Oct 2020 Status changed from recruiting to completed.
- 12 May 2020 Results of assessing specific IgG levels towards Tetanus toxoid and Diphtheria toxoid in infants received DTaP-IPV-Hib-HepB (Infanrix Hexa) and 10-valent protein D conjugated pneumococcal conjugate vaccine (PHiD-CV10 or Synflorix) at age 3, 5 and 11 months published in the Vaccine
- 30 Jan 2014 New trial record